Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.49 |
| ▸ | HPGD | P15428 | 3/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL988295 | 0.98 | LOXL2 (0.54) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL29934082 | 0.86 | LOXL2 (0.56) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL17083281 | 0.86 | LOXL2 (0.56) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL25721981 | 0.86 | TDP1 (0.52) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL14175211 | 0.86 | TDP1 (0.52) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL15862210 | 0.86 | LOXL2 (0.59) | LOXL2MAPTALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL2414389 | 0.85 | LOXL2 (0.47) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL23501653 | 0.85 | LOXL2 (0.54) | LOXL2MAPTALDH1A1CA1CA2 | |
| Hydrochloric Acid SCHEMBL17077487 | 0.85 | LOXL2 (0.54) | LOXL2MAPTALDH1A1CA1CA2 | |
| SCHEMBL17033980 | 0.85 | CA1 (0.56) | MAPTALDH1A1CA1CA2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10188653-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3119757-B1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER (US) | 2018-05-16 | — | — | EP | disclosed |
| US-20180042926-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2018-02-15 | — | — | US | disclosed |
| US-9789110-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2017-10-17 | — | — | US | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-1781661-B1 | VASOPRESSIN V1A ANTAGONISTS | VANTIA LTD (GB) | 2017-06-07 | — | — | EP | disclosed |
| EP-3119757-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | Pfizer Inc. (US) | 2017-01-25 | — | — | EP | disclosed |
| US-20160303125-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | PFIZER INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-9440949-B2 | Diacylglycerol acyltransferase 2 inhibitors | PFIZER INC. (US) | 2016-09-13 | — | — | US | disclosed |
| WO-2015140658-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS FOR USE IN THE TREATMENT OF METABOLIC AND RELATED DISORDERS | PFIZER INC. (US) | 2015-09-24 | — | — | WO | disclosed |
| EP-1781661-A2 | VASOPRESSIN V1A ANTAGONISTS | Ferring B.V. (NL) | 2007-05-09 | — | — | EP | disclosed |
| EP-1740211-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2007-01-10 | — | — | EP | disclosed |
| CN-1867551-A | Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists | PFIZER (US) | 2006-11-22 | — | — | CN | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2006021213-A2 | VASOPRESSIN V1A ANTAGONISTS | FERRING B.V. (NL) | 2006-03-02 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005102389-A2 | COMBINATIONS COMPRISING ALPHA-2-DELTA LIGANDS AND EP4 RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | ASKAT INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10188653-B2 | Diacylglycerol acyltransferase 2 inhibitors | DGAT2, LCLAT1, DGAT1 | LOXL2 196/4885MAPT 1341/4885ALDH1A1 1034/4885 |
| US-20160303125-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, LCLAT1, DGAT1 | LOXL2 196/4885MAPT 1341/4885ALDH1A1 1034/4885 |
| US-20050065188-A1 | Aryl or heteroaryl amide compounds | HRH2, PTGER1, LTB4R2 | LOXL2 433/4885MAPT 3996/4885ALDH1A1 860/4885 |
| US-20180042926-A1 | DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS | DGAT2, LCLAT1, DGAT1 | LOXL2 196/4885MAPT 1341/4885ALDH1A1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.